No matches
Dermatology

Key Pathophysiological Mechanisms of Chronic Spontaneous Urticaria Are Driven by Type 2 Inflammation

Join Dr. Jason Hawkes as he explains the importance of type 2 inflammation in chronic spontaneous urticaria.
Jason Hawkes
MD, MS
Jason Hawkes

Related resources

What is Early Intervention in AD?

What is Early Intervention in AD?

expert video
Systemic Inflammation in AD – Beyond the Skin

Systemic Inflammation in AD – Beyond the Skin

expert video
Dysbiosis, Skin Infections, and Itch

Dysbiosis, Skin Infections, and Itch

expert video
Skin Barrier Dysfunction in AD

Skin Barrier Dysfunction in AD

expert video
Early Intervention and the Potential for Disease Modification in Children With AD

Early Intervention and the Potential for Disease Modification in Children With AD

expert video
Emerging Data on Advanced Systemic Treatments for Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD

expert video
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

expert video
Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

expert video
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

expert video
Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

expert video
Most Burdensome Symptoms Rated by PN Patients

Most Burdensome Symptoms Rated by PN Patients

expert video
Current systemic therapies have been shown to induce remission in a subset of AD patients

Current systemic therapies have been shown to induce remission in a subset of AD patients

expert video
Can advanced systemic therapies modify pathomechanisms in AD?

Can advanced systemic therapies modify pathomechanisms in AD?

expert video
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Podcast
Barrier disruption in AD and the development of environmental and food allergies

Barrier disruption in AD and the development of environmental and food allergies

expert video
CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

Infographic
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

videoanimation
Explore the Global Burden of Pediatric AD (PEDISTAD)

Explore the Global Burden of Pediatric AD (PEDISTAD)

interactivity
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

expert video
Can early intervention modify the course of AD?

Can early intervention modify the course of AD?

expert video
Guideline-Based Diagnosis of Atopic Dermatitis

Guideline-Based Diagnosis of Atopic Dermatitis

interactivity
Type 2 Inflammation Within Skin Tissue in AD

Type 2 Inflammation Within Skin Tissue in AD

expert video
IL-4 Contributes to Systemic Type 2 Inflammation in AD

IL-4 Contributes to Systemic Type 2 Inflammation in AD

expert video
Diving Below the Surface of AD: The Role of Type 2 Inflammation

Diving Below the Surface of AD: The Role of Type 2 Inflammation

expert video
Considerations for Disease Modification in AD

Considerations for Disease Modification in AD

expert video
The Role of Type 2 Inflammation in Moderate-to-Severe AD

The Role of Type 2 Inflammation in Moderate-to-Severe AD

expert video
Identification and Management of AD Uncontrolled With Topical Therapies in Children

Identification and Management of AD Uncontrolled With Topical Therapies in Children

expert video
Epidemiology and Pathophysiology of AD in Children

Epidemiology and Pathophysiology of AD in Children

expert video
Current and Emerging Therapeutic Options for Children With Atopic Dermatitis

Current and Emerging Therapeutic Options for Children With Atopic Dermatitis

expert video
Atopic Dermatitis in Children: Not Just a Skin Disease

Atopic Dermatitis in Children: Not Just a Skin Disease

expert video
Type 2 Inflammation and Its Role in Atopic Dermatitis

Type 2 Inflammation and Its Role in Atopic Dermatitis

expert video
Persistence of AD From Childhood Into Adulthood

Persistence of AD From Childhood Into Adulthood

expert video
Key Treatment Considerations for Management of Atopic Dermatitis in Children

Key Treatment Considerations for Management of Atopic Dermatitis in Children

expert video
Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD

expert video
Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

expert video
Early Intervention and the Potential For Disease Modification in AD

Early Intervention and the Potential For Disease Modification in AD

expert video
Emerging Real-World Data on Advanced Systemic Therapies in AD

Emerging Real-World Data on Advanced Systemic Therapies in AD

expert video
Real-World Effectiveness of Advanced Systemic Treatments in AD

Real-World Effectiveness of Advanced Systemic Treatments in AD

expert video
The Importance of Early Intervention and the Potential for Disease Modification in Patients With AD

The Importance of Early Intervention and the Potential for Disease Modification in Patients With AD

expert video
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Podcast
Chronic Spontaneous Urticaria Mechanism of Disease Animation

Chronic Spontaneous Urticaria Mechanism of Disease Animation

videoanimation
CSU Burden Related to Chronicity and Patient Journey

CSU Burden Related to Chronicity and Patient Journey

expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
The Clinical Presentation of CSU is Heterogeneous

The Clinical Presentation of CSU is Heterogeneous

expert video
The Role of Type 2 Inflammation in Multiple Disease Trajectories

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Infographic
Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

Podcast
Latest Real-World Data on Advanced Systemic Treatments for Patients With AD

Latest Real-World Data on Advanced Systemic Treatments for Patients With AD

expert video

Learning objectives

  • Understand how type 2 inflammation, particularly mast cells, drives wheals, angioedema, and itch in chronic spontaneous urticaria
Tags
mast cellsPathophysiologymechanism of diseaseIL-4Chronic Spontaneous Urticaria
MAT-GLB-2602219 -1.0 -06/2026

About this expert

Dermatology

Jason Hawkes

MD, MS

Dr. Hawkes is a board-certified dermatologist and Investigator at the Oregon Medical Research Center in Portland, OR and is a current Councilor in the International Psoriasis Council and serves on the NPF Medical Board and Scientific Advisory Committee

See author’s profile
Jason Hawkes

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: NorwayChange country/region